The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The NHS’s National Genomic Test Directory has been launched in England. With it comes DPYD gene testing, an important example of pharmacogenomics in cancer care that moves us another step closer to personalised medicine.
https://www.rcpath.org/profession/publications/college-bulletin/april-2021/pharmacogenomics-in-cancer-management.html
Lot 2 Published: Fri 23 Apr 2021 https://bidstats.uk/tenders/?q=yourgene&scope=None#749469695-749404454-27
He is here...https://twitter.com/BrokermanDaniel/status/1385241750889959429
https://bidstats.uk/tenders/?q=yourgene#749207551-749142261-38
Manchester, UK - 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded a Framework Agreement under Public Health England's ("PHE") National Microbiology Framework for Lot 1 (Diagnostic Goods and Services) of the four-lot tender for its Clarigene® SARS-CoV-2 assay and Manchester-based COVID testing service.
PHE's National Microbiology Framework is appointing suppliers to framework agreements for four lots. Lot 1 is the first to be announced and covers the supply of in-vitro diagnostic medical devices and associated services, including for the Company's Clarigene® SARS-CoV-2 PCR assay and the associated clinical laboratory testing services delivered through Yourgene Genomic Services. The term of the Framework Agreement for Lot 1 (and for each subsequent lot, if awarded) is for an initial two years with options to extend by up to a further two years. Lot 1 is a £3bn tender to be satisfied by multiple successful bidders.
Under the National Microbiology Framework, participating public health authorities across the United Kingdom can use call-off contracts to procure goods and testing services from Yourgene under such lots as it is in receipt of a Framework Agreement, but there is no guarantee that such contracts will be forthcoming, nor as to the quantum of any potential call-off contracts may which arise.
Lyn Rees, CEO of Yourgene commented:
"We welcome the opportunity to work with PHE and its sister organisations across the NHS, DHSC and in Wales, Scotland and Northern Ireland to offer our Clarigene® SARS-CoV-2 PCR assay, and our accredited lab testing services, to contain Covid-19 in the near-term and to participate in putting in place a robust testing infrastructure post-pandemic. Yourgene considers that the successful framework award, for which there was a competitive tender process, lends significant credibility to the Clarigene® product and to the Company's COVID testing services. More broadly, we expect the award to support business development outside the scope of this agreement with a growing network of commercial partners, addressing privately funded testing in healthcare and workplace settings."
Ref the twitter furore over the Covid testing bids - https://bidstats.uk/tenders/2021/W09/746193438 The 1 stock currently without any Covid premia but almost certainly bidding is Yourgene Healthcare #YGEN. Covered in full here - https://alignresearch.co.uk/cpt-company/yourgene-health/ Expecting a sharp up day tomo.
https://twitter.com/AlignResearch/status/1368485021724667906
https://twitter.com/Yourgene_Health/status/1362386478349844482
Northern Ireland joins the growing list of countries adopting #DPYD testing for its cancer patients. The Elucigene DPYD kit is widely used across the UK, including in Northern Ireland, to provide routine testing ahead of certain chemotherapy treatments
https://www.bowelcanceruk.org.uk/news-and-blogs/news/bowel-cancer-patients-in-northern-ireland-receive-life-saving-testing-before-starting-chemotherapy/
https://twitter.com/Yourgene_Health/status/1362326177625604097
https://www.yourgene-health.com/infectious-disease/clarigene-ce-ivd/clarigene-feature-notes/93-products/infectious-disease/clarigene-ce-ivd/1760-fen002-independent-validation-of-the-clarigenetm-sars-cov-2-assay-demonstrates-consistently-high-performance-in-line-with-product-claims
https://www.brrmedia.co.uk/broadcasts/6023ea2613605530a6606feb/yourgene-health-trading-update/
https://www.yourgene-health.com/nipt/iona-nx/for-clinical-laboratories/technical-support
COVID-19 update
Throughout the Coronavirus pandemic, our technical support teams have continued to provide the excellent service our customers expect.
They are looking for more workers!
https://www.totaljobs.com/jobs-at/yourgene-health/jobs
Manchester, UK - 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission ("CQC") that the Company's facilities at Citylabs 1.0 in Manchester are now a second accredited location from which to perform diagnostics and screening procedures.
The extension of the Company's current CQC registration allows NIPT testing greater flexibility to operate from both Yourgene Health locations in Manchester, and confirms that the Company's COVID-19 testing services meet the demanding standards of the CQC. As announced on 28 September 2020, the launch of Yourgene Genomic Services consolidates the Company's established NIPT and rapidly growing COVID-19 testing services in Manchester and this accreditation supports this strategy. The CQC registration supports the Company's continued scale up in capacity for COVID-19 testing for both private and public market segments.
The CQC is an independent regulator of health and social care in England and ensures, amongst other things, that services are safe, high-quality, effective and meet legal standards.
The extension of the Company's current CQC registration allows NIPT testing greater flexibility to operate from both Yourgene Health locations in Manchester, and confirms that the Company's COVID-19 testing services meet the demanding standards of the CQC. As announced on 28 September 2020, the launch of Yourgene Genomic Services consolidates the Company's established NIPT and rapidly growing COVID-19 testing services in Manchester and this accreditation supports this strategy. The CQC registration supports the Company's continued scale up in capacity for COVID-19 testing for both private and public market segments.
The CQC is an independent regulator of health and social care in England and ensures, amongst other things, that services are safe, high-quality, effective and meet legal standards.
Elucigene DPYD tests to be used routinely in Wales
Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments
Manchester, UK - 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely screen all cancer patients prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.
Wales is the first nation in the UK to implement this screening programme and offer the DPYD test to all patients, with over 400 samples already taken and 6% of patients coming back positive. All Wales Medical Genomics Service (AWMGS), which provides specialist genetic services to individuals with, or concerned about rare genetic conditions, commenced a pilot phase earlier this year which was successful, leading to the launch of the service this week. It has led to all health boards across Wales routinely offering the DPYD test to cancer patients, of which Yourgene is the sole provider.
Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.
Yourgene will be providing the Elucigene DPYD tests to screen for approximately 200 patients each month for the next year. If 2,400 patients are screened, at the positive rate of 6% continues, we anticipate 144 cancer patients will be prevented from having toxic chemotherapy reactions.
Lyn Rees, CEO of Yourgene, commented: "It is fantastic to see this form of personalised medicine implemented across Wales, allowing the quality of care for cancer patients to improve, ultimately saving lives. Yourgene is proud to be sole supplier of DPYD so soon after its launch in September 2019 and looks forward to similar schemes being rolled out across the UK."
https://obndigitalyourgene.obn.expoplatform.com/
OBN Digital Event:
'COVID Workplace Testing'
Kindly hosted by Yourgene Health
This edition of OBN’s Digital Event series is kindly hosted by Yourgene Health. During the event, Yourgene Health will introduce their COVID Testing options, their fast track development process for a CE marked molecular diagnostic test, running the test in a COVID lab setting and how the test is being used within the workplace.
The session will be run in a live, digital format, with registration COMPLIMENTARY for both OBN Members and Non-members.
Yourgene's COVID-19 response - Clarigene® SARS-CoV-2 test
COVID was declared a global health crisis in March and the need for accurate diagnosis quickly became an issue. Yourgene Health started development of their Clarigene® SARS-CoV-2 molecular diagnostic assay in April 2020 and fast-tracked development to a CE marked test by July 2020. Covid testing was rolled out in their genomic services laboratory in Manchester in July 2020.
Workplace testing and it's impacts - the voice of experience
The Yourgene facility in Manchester is used by numerous companies and schools for their COVID testing strategies. Learn from two of their partners about the process for logistics, sample collection, testing and results provision.
Keynote Speakers:
Paul Docherty, Business Development Director, Yourgene Health
Bhavika Patel, Director of Genomics, Yourgene Health
Clive Minihan, Director, Recova
Steve Dollard, Operations Director, MediSkills
https://www.thebusinessdesk.com/northwest/news/2065748-new-testing-tech-will-expand-biotech-groups-international-reach
The AIM-listed business, which focuses on prenatal testing and COVID-19 testing technology, said its IONA Nx test seeks to offer clinical labs a high performing, flexible, scalable and innovative NIPT service in-house.
Yourgene said it expects to see uptake of the product in other European territories, where it will use its recently strengthened commercial team in Europe. It will transition existing customers in the UK and France.
The group said it will also target the Australian market.
Yourgene said the new system offers one of the fastest automated workflows on the market and can be performed in just two days, three for manual workflow.
Chief executive, Lyn Rees, said: “We have already expanded our European sales team with key appointments in UK, France, Germany to support the commercial roll-out of the IONA Nx and we will look to give updates on key milestones such as regulatory approval and new customer wins.
“Our IONA test has a strong reputation for reliability and accuracy and was the first CE marked NIPT product for the European market.
“The new IONA Nx combines this gold standard for reliability and accuracy with a market-leading sequencer and we believe this will be a strong driver of growth in the future.”
He added: “We expect to see accelerated double digit growth in our NIPT business this calendar year.
“We are confident that a this will be delivered through a mix of organic growth across our existing NIPT customer base, the transition of existing customers to IONA Nx in current territories, as well as through securing new customers and commencing sales in new territories.”
https://www.insidermedia.com/news/north-west/yourgene-buoyed-by-exceptional-progress
Speaking to Insider, chief executive Lyn Rees hailed the impact of Elucigene, which was acquired in April 2019.
"We did anticipate a big impact that quickly," she said.
"The synergy savings were identified as part of diligence and the sales growth is part of our range-selling initiative.
"There was only one common customer between the two entities, so we instantly went from customers in 30 countries to 60 countries."
Rees said the company had made "expectional progress over the last 24 months".
"The team has worked tirelessly to deliver the plan and we are delighted to have reached this stage. We realise, however, that there is a long way to go to achieve our five-year strategic plan so we're upbeat, yes, but also determined to finish the long-term job."
Asked how much of the company's focus will be on the coronavirus, Rees added: "We are a molecular diagnostics business which supplies the NIPT, reproductive health and oncology markets.
"Our Clarigene range for Covid-19 PCR tests represents our first move into the infectious disease market and while the commercial opportunity is large, we are making sure that we don't lose any attention or focus on the more established product ranges.
"Covid has changed the way we live, work and go about our day to day lives. I suspect that has changed for a long time to come yet and we need to start adapting.
"We are determined to be part of the solution to find the new norm. Whether that's testing to get on a plane to go on holiday or to return to work or school, we hope that our technology will help us all find that new normal."